1. "Neal Rosen"
  2. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (220)
  2. Meeting Abstract (185)
  3. Conference Paper (7)
  4. Book Section (2)
  5. Editorial (2)
  6. Review (2)
  7. Research Letter (1)
Groups
  1. Breast Medicine Service (419)
  2. Department of Medicine (419)
  3. GSK Faculty (419)
  4. Molecular Pharmacology and Chemistry Program Faculty (419)
  5. Sloan Kettering Institute Faculty (419)
  6. Solid Tumor Oncology Division (419)

More Groups

People
  1. Neal Rosen (419)
  2. David Solit (155)
  3. Sarat Chandarlapaty (56)
  4. Howard Scher (44)
  5. Christine Pratilas (36)
  6. Laura Sepp-Lorenzino (36)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (13)
  4. 2021 (13)
  5. 2020 (12)
  6. 2019 (11)

More Years

Publications
  1. Cancer Research (98)
  2. Clinical Cancer Research (42)
  3. Proceedings of the American Association for Cancer Research Annual Meeting (36)
  4. Journal of Clinical Oncology (23)
  5. Cancer Discovery (22)
  6. Cancer Cell (15)

More Publications

Publishers
  1. American Association for Cancer Research (207)
  2. Nature Publishing Group (37)
  3. American Society of Clinical Oncology (24)
  4. Cell Press (19)
  5. Elsevier Inc. (16)
  6. National Academy of Sciences (11)

More Publishers

Results (419)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRAF — A tumour-agnostic drug target with lineage-specific dependencies
    Review

    Hanrahan, A. J.; Chen, Z.; Rosen, N.; Solit, D. B.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions
    Meeting Abstract

    Chen, M. F.; Yang, S. R.; Tao, J.; Desilets, A.; Rosen, E.; Gong, Y.; Mullaney, K. A.; Kris, M. G.; Arcila, M. E.; Donoghue, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Molecular characterization of acquired resistance to KRAS(G12C)–EGFR inhibition in colorectal cancer
    Journal Article

    Yaeger, R.; Mezzadra, R.; Sinopoli, J.; Bian, Y.; Marasco, M.; Kaplun, E.; Gao, H.; Zhao, H. Y.; Paula, A. D. C.; Zhu, Y.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Estrogen receptor expression and ER dependent breast tumor growth are dependent on translation initiation factor EIF4A
    Meeting Abstract

    Boyer, J. A.; Dorso, M. A.; Amor, C.; Reiter, J.; Xu, J.; de Stanchina, E.; Wendel, H. G.; Chandarlapaty, S.; Rosen, N.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Migration of V600E-expressing cells is suppressed by ERK-dependent feedback inhibition of RAC1 and rescued in melanoma by secondary mutations
    Meeting Abstract

    Gadal, S.; Boyer, J. A.; Li, H.; Fan, N.; Chan, E.; Romin, Y.; De Stanchina, E.; Yeager, R.; Bosenberg, M.; Todorova, K. M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Combining a novel MEK inhibitor with immunomodulation to promote an anti-tumor response
    Meeting Abstract

    Dong, L.; Choi, H.; Budhu, S.; Schulze, I.; Verma, S.; Mehanna, N.; Rosen, N.; Merghoub, T.; Wolchok, J.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Reversibility of tumor adaptations to PI3K inhibition decreases as a function of time
    Meeting Abstract

    Mukherjee, R.; de Stanchina, E.; Chandarlapaty, S.; Rosen, N.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • RAF-Independent MEK mutations drive histiocytic neoplasms in vivo and are sensitive to single-agent ERK inhibition in patients
    Meeting Abstract

    Durham, B. H.; Singer, M. E.; Benbarche, S.; Erickson, C.; Rahman, J.; Solit, D. B.; Witkowski, M.; Rosen, N.; Abdel-Wahab, O.; Diamond, E. L.
    Blood (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study
    Meeting Abstract

    Burris, H. A. 3rd; Ulahannan, S. V.; Haura, E. B.; Ou, S. H. I.; Capasso, A.; Munster, P. N.; Kitai, H.; Wang, Z.; Hayes, J.; Tao, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save